MARKET

MCRB

MCRB

Seres
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.700
+0.270
+7.87%
Closed 16:00 03/30 EDT
OPEN
3.440
PREV CLOSE
3.430
HIGH
3.840
LOW
3.440
VOLUME
327.76K
TURNOVER
--
52 WEEK HIGH
7.39
52 WEEK LOW
2.020
MARKET CAP
263.25M
P/E (TTM)
-2.7742
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MCRB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MCRB stock price target is 8.63 with a high estimate of 15.00 and a low estimate of 3.750.

EPS

MCRB News

More
  • Seres Therapeutics completes enrollment in late-stage C. diff study
  • Seeking Alpha - Article · 20h ago
  • Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates
  • Business Wire · 21h ago
  • Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors
  • Business Wire · 03/23 12:00
  • Edited Transcript of MCRB earnings conference call or presentation 2-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/19 23:56

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About MCRB

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
More

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.